Gérard Hascoët
CHAIRMAN

is venture partner in Medical Devices. After graduating from E.C.E (Ecole Centrale d'Electronique de Paris) he began his career in 1972 at CGR, the Medical Devices Subsidiary of the French Thomson Group, where he held various management positions. From 1985 to 1993, he was Founder, Chairman and CEO of Technomed International a $ 40 Million sales company developing non invasive technologies dedicated to therapy. He grew the company to its IPO on the French Second Marché. From 1993 to 1997, he was Chairman and CEO of IMMI, a start up that he co founded developing Neurosurgery Image guided Robotic systems. The company was sold in 1997 to the US based company ISS. Also from 1993 to 1999 he was Founder, Chairman and CEO of Sometec, a start up developing technologies in Anesthesiology and Intensive Care. The company was sold in 1999 to the US based Nasdaq listed company ARROW International. Gérard remained consultant for Arrow until 2001.

Gérard Hascoët is Chairman of the Board of Valtronic Technologies (Switzerland), Chairman of the Board of Pro-Med (Austria), Director of the Board of EndoArt (Switzerland), Director of the Board of Altamir (France) Director of the Board of Dupont Medical (France), and Vice Chairman of BIOCRITT (France). He is Venture Partner for the French based Venture Capital firm Sofinnova Partners.

Antoine Papiernik

is general partner and invests in life sciences. He joined Sofinnova Partners www.sofinnova.fr in 1997. Antoine has an MBA from the Wharton School (University of Pennsylvania). He began his career in London as product manager at Unilever's Health/Beauty division. He then spent four years in Prague, first as consultant, then as investor for CDC-Participations (Caisse des Dépôts Group). He then moved to the newly formed venture capital firm CDC-Innovation where he invested exclusively in life sciences. Antoine was an initial investor in Actelion, a Swiss biopharmaceuticals company that is now listed on the Zürich stock exchange. He has also invested in and is a board member of NovusPharma (quoted on the Nuovo Mercato in Milan), Biolipox, Diatos, SpineVision, EndoArt and Addex.

DI Burkhard Feurstein

is one of four partners of Vienna-based gcp gamma capital partners (www.gamma-capital.com); he invests in medical devices and biotechnology companies. Burkhard studied physics at the technical university of Vienna and worked for 12 years at FGG, a state-owned development bank, in financing Austrian-based technology projects and international expansion of SME's and for 5 years as an independent consultant manager.

In 2000 he joined Investkredit Bank to launch their tech-venture fund that finally became part of the independent VC-firm gcp. Burkhard has also invested in CNSystems, igeneon and ORIDIS and is a board member in two of these companies.